Compare MYD & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYD | BCYC |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.7M | 476.6M |
| IPO Year | N/A | 2019 |
| Metric | MYD | BCYC |
|---|---|---|
| Price | $10.43 | $6.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $18.73 |
| AVG Volume (30 Days) | ★ 253.1K | 241.1K |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.76 | $6.03 |
| 52 Week High | $11.30 | $15.47 |
| Indicator | MYD | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 45.41 |
| Support Level | $10.30 | $6.73 |
| Resistance Level | $10.46 | $7.28 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 68.52 | 9.78 |
Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes. The fund invests a majority of its assets in municipal bonds exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax). These bonds are predominantly long-term (with a maturity of more than ten years at the time of investment), and rated as investment grade, or deemed to be of comparable quality by the investment adviser at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.